249 related articles for article (PubMed ID: 25230744)
1. Comparison of standard-dose and half‑dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: A propensity score matching analysis.
Nishikawa H; Osaki Y; Endo M; Takeda H; Tsuchiya K; Joko K; Ogawa C; Taniguchi H; Orito E; Uchida Y; Izumi N;
Int J Oncol; 2014 Dec; 45(6):2295-302. PubMed ID: 25230744
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.
Shiozawa K; Watanabe M; Ikehara T; Kogame M; Matsui T; Okano N; Kikuchi Y; Nagai H; Ishii K; Makino H; Igarashi Y; Sumino Y
Hepatogastroenterology; 2014 Jun; 61(132):885-91. PubMed ID: 26158136
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Estfan B; Byrne M; Kim R
Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
[TBL] [Abstract][Full Text] [Related]
5. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
7. Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting.
Kondo M; Morimoto M; Ishii T; Nozaki A; Fukuda H; Numata K; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Shibuya A; Okuse C; Suzuki M; Sakamaki K; Morita S; Maeda S; Tanaka K
J Dig Dis; 2015 Mar; 16(3):143-51. PubMed ID: 25495751
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.
Kudo M; Ikeda M; Takayama T; Numata K; Izumi N; Furuse J; Okusaka T; Kadoya M; Yamashita S; Ito Y; Kokudo N
J Gastroenterol; 2016 Dec; 51(12):1150-1160. PubMed ID: 27106231
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
Miyaki D; Aikata H; Kan H; Fujino H; Urabe A; Masaki K; Fukuhara T; Kobayashi T; Naeshiro N; Nakahara T; Kawaoka T; Hiramatsu A; Takahashi S; Ishikawa M; Kakizawa H; Awai K; Chayama K
J Gastroenterol Hepatol; 2013 Dec; 28(12):1834-41. PubMed ID: 23808713
[TBL] [Abstract][Full Text] [Related]
10. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
[TBL] [Abstract][Full Text] [Related]
12. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Xu L; Gao H; Huang J; Wang H; Zhou Z; Zhang Y; Li S; Chen M
J Gastroenterol Hepatol; 2015 Jun; 30(6):1032-9. PubMed ID: 25639513
[TBL] [Abstract][Full Text] [Related]
13. Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Tong X; Xu X; Shi H; Liu S; Yang Z
PLoS One; 2015; 10(2):e0117168. PubMed ID: 25689846
[TBL] [Abstract][Full Text] [Related]
14. Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma.
Santini D; Addeo R; Vincenzi B; Calvieri A; Montella L; Silletta M; Caraglia M; Vespasiani U; Picardi A; Del Prete S; Tonini G
Expert Rev Anticancer Ther; 2012 Oct; 12(10):1283-8. PubMed ID: 23094801
[TBL] [Abstract][Full Text] [Related]
15. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
Llovet JM; Decaens T; Raoul JL; Boucher E; Kudo M; Chang C; Kang YK; Assenat E; Lim HY; Boige V; Mathurin P; Fartoux L; Lin DY; Bruix J; Poon RT; Sherman M; Blanc JF; Finn RS; Tak WY; Chao Y; Ezzeddine R; Liu D; Walters I; Park JW
J Clin Oncol; 2013 Oct; 31(28):3509-16. PubMed ID: 23980090
[TBL] [Abstract][Full Text] [Related]
16. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS
J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
[TBL] [Abstract][Full Text] [Related]
18. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma.
Cho JY; Paik YH; Park HC; Yu JI; Sohn W; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2014 May; 34(5):795-801. PubMed ID: 24350564
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
[TBL] [Abstract][Full Text] [Related]
20. Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.
Takeda H; Nishikawa H; Osaki Y; Tsuchiya K; Joko K; Ogawa C; Taniguchi H; Orito E; Uchida Y; Izumi N;
Liver Int; 2015 May; 35(5):1581-9. PubMed ID: 24836552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
